Memantine Hydrochloride Capsule, Extended Release
Product Images NDC 70436-054

11 FDA label images from Slate Run Pharmaceuticals, Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 70436-054). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Slate Run Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

14mg-30ct (14mg 30ct)

14mg-30ct (14mg 30ct)
Memantine Hydrochloride Extended-Release Capsules 14 mg, oral dosage form, from Slate Run Pharmaceuticals. This packaging label indicates a quantity of 30 capsules. It includes storage instructions and manufacturer information, showing manufacture by Yichang Humanwell in China and distribution by Slate Run Pharmaceuticals in Ohio.*
FDA Label Image

14mg-90ct (14mg 90ct)

14mg-90ct (14mg 90ct)
Label for Memantine Hydrochloride Extended-Release Capsules 14 mg, manufactured by Slate Run Pharmaceuticals, LLC. The label indicates a package size of 90 capsules. It includes storage instructions, dispensing guidelines, barcode, and manufacturer details, with the dosage form as oral extended-release capsules.*
FDA Label Image

21mg-30ct (21mg 30ct)

21mg-30ct (21mg 30ct)
Label for Memantine Hydrochloride Extended-Release Capsules 21 mg by Slate Run Pharmaceuticals. The label shows a package containing 30 oral extended-release capsules. Includes storage instructions, manufacturer information for Yichang Humanwell Oral Solid Dosage Plant in China, and distributor details in Columbus, Ohio.*
FDA Label Image

Image Description (28mg 30ct)

Image Description (28mg 30ct)
Label for Memantine Hydrochloride Extended-Release Capsules, 28 mg strength, containing 30 capsules. The label states it is an oral prescription drug manufactured by Yichang Humanwell and distributed by Slate Run Pharmaceuticals, LLC. Storage instructions and general dispensing information are also shown, including keeping the product out of children's reach and storing at controlled room temperature.*
FDA Label Image

Image Description (28mg 90ct)

Image Description (28mg 90ct)
Memantine Hydrochloride Extended-Release Capsules 28 mg label for oral use, manufactured by Yichang Humanwei and distributed by Slate Run Pharmaceuticals, LLC. The label states a 90-capsule count and includes storage instructions and dispensing advice with a barcode and NDC 70436-057-06.*
FDA Label Image

7mg-30ct (7mg 30ct)

7mg-30ct (7mg 30ct)
Memantine Hydrochloride Extended-Release Capsules, 7 mg strength, box label for 30 capsules by Slate Run Pharmaceuticals, LLC. The label includes storage instructions, dosage form, and manufacturing details from Yichang Humanwell. The product is prescription only and includes a barcode.*
FDA Label Image

Chemical Structure (Chemical Structure)

Chemical Structure (Chemical Structure)
Chemical structure diagram depicting memantine hydrochloride, showing its distinctive cage-like tricyclo ring system with attached amine and methyl groups, consistent with the active ingredient memantine hydrochloride.*
FDA Label Image

Figure 1 (Figure 1)

Figure 1 (Figure 1)
A line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment comparing Memantine Hydrochloride Extended-Release Capsules 28 mg/AChEI and Placebo/AChEI. The x-axis shows weeks of treatment, while the y-axis shows mean change with standard error margins. The graph includes markers for clinical improvement and decline.*
FDA Label Image

Figure 2 (Figure 2)

Figure 2 (Figure 2)
A line graph showing the cumulative percentage of patients on the y-axis versus SIB (Severe Impairment Battery) change from baseline on the x-axis. It compares two groups: Memantine Hydrochloride Extended-Release Capsules 28 mg plus AChEI and Placebo plus AChEI, with a legend distinguishing these groups. The graph illustrates the distribution of patients' responses to treatment over a range of SIB changes.*
FDA Label Image

Figure 3 (Figure 3)

Figure 3 (Figure 3)
A line graph comparing the mean Clinical Interview-Based Impression of Change Plus (CIBIC-Plus) scores over 24 weeks of treatment between Memantine Hydrochloride Extended-Release Capsules 28 mg (black line with diamonds) and placebo (gray line with squares). The x-axis represents weeks of treatment (0 to 24), and the y-axis shows the mean CIBIC-Plus scores with standard error bars, ranging from 3.6 to 4.4. A horizontal dashed line at score 4 indicates the threshold between clinical improvement and clinical decline.*
FDA Label Image

Figure 4 (Figure 4)

Figure 4 (Figure 4)
A bar graph comparing the percentage of patients across different CIBIC Plus Rating categories for Memantine Hydrochloride Extended-Release Capsules 28 mg versus placebo. Categories include marked improvement, moderate improvement, minimal improvement, no change, minimal worsening, moderate worsening, and marked worsening, with the Y-axis representing percentage of patients and the X-axis representing the CIBIC Plus Rating levels.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.